ProMetic Life Sciences Inc.
TSX : PLI
OTCQX : PFSCF

ProMetic Life Sciences Inc.

April 12, 2013 07:00 ET

ProMetic Begins Trading on OTCQX®

LAVAL, QUEBEC--(Marketwired - April 12, 2013) - ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), ("ProMetic" or the "Corporation") announced today that its common shares have commenced trading on OTCQX International under the symbol PFSCF. OTCQX International is a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies listed on a qualified stock exchange in their home country.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS) will serve as ProMetic's Principal American Liaison ("PAL") on the OTCQX, responsible for providing professional guidance on the OTCQX requirements.

"More than 50% of our revenues come from U.S. clients and strategic partners; this combined with our growing U.S. based subsidiary, the recent grant of an orphan drug designation by the U.S. FDA as well as various upcoming US IND filings has made it necessary to accommodate the growing demand for our securities from U.S. based investors", mentioned Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. "Joining OTCQX fits perfectly with our strategy to further develop our presence in the U.S.", added Mr. Laurin.

ProMetic also announced today that its company information would be made available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of ProMetic will be published in the Daily News Section of Standard & Poors's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. Standard & Poor's Corporation Records is available in print, CD-ROM, and via the web at www.netadvantage.standardandpoors.com as well as through numerous electronic vendors. The company information about ProMetic to be made available through this program includes an in-depth description of the ProMetic's business operations, share price, dividend history, shares outstanding, company financial position, earnings, and full income statement and balance sheet.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a global biopharmaceutical company specializing in the design of small molecules that mimic unique and specific interactions between proteins, research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics, drug development, proteomics and the elimination of pathogens. ProMetic is also active in developing its own novel therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 26 of ProMetic's Annual Information Form for the year ended December 31, 2012, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

Contact Information

  • Pierre Laurin
    President and CEO
    ProMetic Life Sciences Inc.
    p.laurin@prometic.com
    +1.450.781.0115

    Frederic Dumais
    Director, Communications and Investor relations
    ProMetic Life Sciences Inc.
    f.dumais@prometic.com
    +1.450.781.0115